RxDoctor Payments Data

John Livingstone, MD

Neurology · Newport News, VANPI 1841219888

Payments from drug & device makers

$2,115in general payments, 2019–2025

Across 51 payments — averaging $41.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$1K
  • Ceribell, Inc.$211
  • W. L. Gore & Associates, Inc.$147
  • AbbVie$134
  • Novartis$131
  • AstraZeneca$75
  • plus $90 from 3 others

What the payments were for

  • Food & beverage$1,29095%
  • Education$755%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen30$1,326
Ceribell, Inc.1$211
W. L. Gore & Associates, Inc.1$147
AbbVie(2 entities)8$134
Novartis6$131
AstraZeneca1$75
Amgen(2 entities)2$36
Lundbeck LLC1$31
TG Therapeutics, Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,115 in reported general payments places this provider in the 50th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$98,427
Medicare patients
817
Services billed
1,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate24$119,254
FingolimodFingolimod Hcl12$86,614
Dimethyl Fumarate35$82,706
NuedextaDextromethorphan Hbr/Quinidine28$58,988
Teriflunomide18$54,762
RexultiBrexpiprazole17$42,956
Aimovig AutoinjectorErenumab-Aooe35$26,038
XcopriCenobamate19$22,101
Lacosamide144$21,087
QuliptaAtogepant15$18,014
Nurtec OdtRimegepant Sulfate17$17,331
Levetiracetam462$15,523
Emgality PenGalcanezumab-Gnlm13$14,204
Carbamazepine ErCarbamazepine102$11,480
VimpatLacosamide11$10,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$134$18,01415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 474 neurology providers in Virginia.

Other neurology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →